N@N

PRINCETON, N.J.--([ BUSINESS WIRE ])--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that at the Novation Supplier Summit Conference in February the Companyas MEDIHONEY was recognized as a finalist for the Novation 2011 Innovative Technology Award. Novation is the leading health care supply contracting company for the members of VHA Inc. and UHC, two national health care alliances, and Provista, LLC.

"We are proud to offer the leading brand of honey-based dressings and look forward to the continued expansion of this product."

Derma Sciencesa MEDIHONEY product line was selected as a finalist by Novation members, based on the productas impact on patient care and improving patient outcomes.

MEDIHONEY is a unique line of patented wound care dressings containing Active Leptospermum Honey from New Zealand which possess unique qualities that make them ideal for the management of chronic and acute wounds and burns. With a strong and growing base of peer reviewed evidencea" including several large-scale randomized controlled studies- MEDIHONEY dressings have shown to be effective for debridement and helping to advance hard to heal stalled wounds through the healing process.

aRecognition as a finalist in this competition is an achievement that shows the value of our MEDIHONEY product line in the wound care industry, and is a reflection of our partnership with Novation and the membership served by Novation,a stated Derma Sciencesa CEO, Ed Quilty. aWe are proud to offer the leading brand of honey-based dressings and look forward to the continued expansion of this product.a

About Derma Sciences, Inc.

Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings. Derma Sciences has successfully completed the treatment phase of a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, a novel pharmaceutical drug under development for accelerated wound healing and scar reduction. Its MEDIHONEY product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB for better management of wound exudate, and BIOGUARD for infection prevention.

For more information please visit [ www.dermasciences.com ].

Forward-Looking Statements

Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release or that are otherwise made by or on behalf of the Company. Factors that may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's filings with the U.S. Securities and Exchange Commission.